Humacyte, Inc. (HUMA) income statement
HUMANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 2/30
$0.50−0.04 (-7.27%)
Close on Nov 17, 2026Market cap $139.18MP/E –Yield –
Humacyte, Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, TTM
- Gross margin
- -494.6%
- Operating margin
- -5240.8%
- Net margin
- -4560.8%
- Return on equity, FY2025
- 164.8%
Financial strength
- Current ratio
- 6.21
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 534.5%
Valuation
- P/E ratio
- –
- Price to sales
- 65.62
- Price to book
- 4.45
- Dividend yield
- –
See a number that looks wrong?